The discontinuation rate due to side effects was 6.1% for Zepbound and 8% for Wegovy. On Stocktwits, sentiment toward Eli ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual ...

Eli Lilly said lower prices for the company’s weight-loss drug trimmed revenue in the quarter, but that demand remained ...